Prometheus Adds Cancer Diagnostics

Xconomy San Diego — 

San Diego’s Prometheus Laboratories says it has signed a licensing and collaboration deal with Rosetta Genomics, an Israeli company that does commercial molecular diagnostic tests at its lab in Philadelphia, PA. Under the agreement, Prometheus will make an $8 million equity investment in Rosetta and gets rights to three micro-RNA-based cancer diagnostic tests. In addition, the two companies agreed to collaborate to develop two new gastroenterology tests.